Zhou M, Gao D, Chai X, Liu J, Lan Z, Liu Q, Yang F, Guo Y, Fang J, Yang L, Du D, Chen L, Yang X, Zhang M, Zeng H, Lu J, Chen H, Zhang X, Wu S, Han Y, Tan J, Cheng Z, Huang C, Wang W
BGI Diagnosis Co., Ltd, Shenzhen, China.
Tissue Antigens. 2015 Jan;85(1):20-8. doi: 10.1111/tan.12477. Epub 2014 Nov 24.
Next generation sequencing (NGS)-based human leukocyte antigen (HLA) typing was used for ultra large-scale genotyping of registry donors for the China Marrow Donor Program (CMDP). More than 79,000 samples were subjected to HLA genotyping at 4-digit allelic level without ambiguities for HLA-A, -B, -C, DRB1 and DQB1 loci, with throughput up to 2068 samples per lane in a HiSeq flow cell (eight lanes per run), and cost reduced by 95% compared with that of Sanger-based typing. Two percent of randomly selected samples were quality control (QC) tested at 4-digit allelic level by the CMDP QC laboratory, yielded a concordance of 99.72%. These results demonstrate that NGS is a cost effective and valuable tool for HLA typing of registry donors.
基于新一代测序(NGS)的人类白细胞抗原(HLA)分型被用于中国造血干细胞捐献者资料库(CMDP)登记捐献者的超大规模基因分型。超过79000份样本在HLA-A、-B、-C、DRB1和DQB1位点进行了4位等位基因水平的HLA基因分型,结果明确无误,在HiSeq流动槽中每个泳道的通量高达2068个样本(每次运行8个泳道),与基于桑格测序的分型相比成本降低了95%。CMDP质量控制(QC)实验室对随机选择的2%样本进行了4位等位基因水平的质量控制检测,一致性为99.72%。这些结果表明,NGS是登记捐献者HLA分型的一种经济高效且有价值的工具。